MedWatch

Ambu's expectations for the new financial year disappoint analysts

After downgrading twice during the financial year 2020/2021 and with a final organic growth of 16 percent, Ambu's target for 2021/2022 is an organic growth of 15-19 percent, which is considerably less ambitious than what analysts had in mind.

Photo: PR / Ambu

Ambu's goals for the new 2021/2022 financial year are considerably more conservative than what the market had hoped for.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs